HOME ABOUT CONTACT PREVIOUS ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Intelligent Sensor Informs You to Change a Diaper via SMS       » University of Manchester & A*STAR ongoing partnership- Joint PhD programme       » Philippines Healthcare & New Digital Platform, MyDoc.       » Tapping on ASEAN'S Healthcare Opportunities through Singapore       » ASEAN: The New Playing Field for Global Medical Device Companies       » The Burden of Great Potential: the ASEAN Economic Community & Biopharmaceuticals       » When there is no Queen in the house, Asian Hive Bees Avoid Risky Foraging for Reproduction       » XELJANZTM (Tofacitinib Citrate), A new class of treatment for Rheumatoid Arthritis Approved in Singapore      
EDITORIAL
Dawn of a new biotech era
We are kicking off the New Year with a refreshed look and content line-up at APBN. In this issue, we take a closer look at nanotechnology — an area of research that holds much potential (much like the beginning of a New Year).

The emergence of nanotechnology came about in the 1980s, a concept popularized and founded by K. Eric Drexler, who spent the next ten years communicating this idea and engaging himself in the field. Nanotechnology is thought to hold the key to many real-world problems — from the domain of medicine to that of machinery — based on the concept of constructing things from the bottom up by manipulating the very, very tiny. It was only at the turn of the new millennia, however, that nanotechnology was given more awareness; and raised more controversy; due to its myriad of possible applications.

Mihail (Mike) Roco of the U.S. National Nanotechnology Initiative describes four generations of nanotechnology development. The first era, he says, is that of passive nanostructures — materials designed to perform one task. The second era, which is the phase we are currently in, introduces active nanostructures for multitasking, like actuators, drug delivery devices, and sensors. The third generation, Roco predicts, will feature nanosystems with interacting components which finally culminates in the fourth phase where nanosystems are integrated, and functioning much like mammalian cells.

We are beginning to see the commercialization of nanotechnology. For example, nanocages are being built for drug delivery purposes, and nanofilms are emitting vapors to protect fruits and vegetables while also extending shelf-life. The latter example is a project launched between researchers from Tamil Nadu Agriculture University (TNAU) and collaborators in Canada and India. They are studying, over a period of 30 months, nanomaterials impregnated with synthetic versions of an agent called hexanal — responsible for fruit and vegetable deterioration — which helps extend the freshness and shelf-life of produce by targeting an enzyme called phospholipase-D.

There are also FDA approved treatments that are considered “nanotechnology”. One such example is Abraxane, a nanoparticle formulation of albumin and Doxil — a liposomal formulation of a chemo drug. These products are, however, not exploiting all the features that nanotechnology can bring to the field of therapeutics. There are currently clinical trials in place for nano-based therapeutics that possess multi-functions for Phase I of cancer — an indication that the potential application of nanotechnology in this field could be immense.

Despite the hype that surrounds nanotechnology, one major concern is toxicity. It is unclear how and what toxicity nanoparticles have. Some new products like cleaners and coatings are appearing in the market without answering this because there are no regulations on them. What may be harmless at a macro or chemical level may have different effects on the body as a nanoparticle. There has not been a fatal event thus far that can be attributed to the nanoparticles in clinical trials or otherwise. It is heartening that in general, most of the nanoparticles in clinical trials are both showing reduced side effects and not revealing new ones. However, this does not undermine the importance of studying the long term implications of nanotechnology applications.

Here’s wishing you an inspiring and fruitful 2013!


Sulastri Kamis
Editor
Asia Pacific Biotech News

Check out our new website at www.asiabiotech.com
Sign up for our mailing list to get updates at www.worldscientific.com/page/newsletter-sign-up
Air your views and suggestions by writing to in to the editorial team (Letters to the Editor) at biotech_edit@wspc.com

Click here for the complete issue.

EDITORS' CHOICE  

Credits to: American Chemical Society
COLUMNS  

APBN Editorial Calendar 2015
Trends and Predictions for 2015 Robotics in Healthcare Nutrition Universal Health Coverage
Start-Up Biotech Companies Preventative and Translational Medicine Biofuels ASEAN Economic Community and Asia's Life Sciences Industry
Big Data: Healthcare and Drug Development Antibody Engineering in Japan Christmas Edition
APBN Editorial Calendar 2016
Korea's Biotechnology Industry Nutrition and Allergies: Are we, Too Clean? Medical Devices and Technology: Innovation that leaves an Inspiration Tobacco Smoking: The 'Real' Cost of One Cigarette
Life-Saving Opportunities: A Guide to Regenerative Medicine Occupational Health Water Technology Olympics: Evolution of Sports
Respiratory: Seasonal flu viruses
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» Editorial Enquiries: biotech_edit@wspc.com
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   Ms PoPo Kwok or Ms Sok Ching Lim
Copyright© 2015 World Scientific Publishing Co Pte Ltd  •  Privacy Policy